Sperti Drug Products, Inc., et al.; Withdrawal of Approval of 40 New Drug Applications

Özet

The Food and Drug Administration (FDA) is withdrawing 40 new drug applications (NDA's). The basis for the withdrawals is that the holders of the applications have repeatedly failed to file required annual reports on these NDA's.